arrow_back Back to App

Nullifying Mifepristone Access Changes: Reverting to Prior Regulations

This bill aims to reverse the January 2023 modifications made by the Food and Drug Administration (FDA) regarding the use of the abortion pill mifepristone. If passed, it would reinstate previous, more restrictive rules for accessing this medication, potentially impacting how citizens obtain it.
Key points
Nullifies FDA's 2023 changes to mifepristone regulations, reverting to previous rules.
Prohibits the Department of Health and Human Services from implementing similar changes in the future.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_679
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
Process start date: 2025-01-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_679.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-01-23.

What are the main provisions?

Key points include:

  • Nullifies FDA's 2023 changes to mifepristone regulations, reverting to previous rules.
  • Prohibits the Department of Health and Human Services from implementing similar changes in the future.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Harshbarger, Diana [R-TN-1].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Courts and Law